Current Evidence of Maternal Infection With Chlamydia trachomatis and Preeclampsia Risk
American Journal of Reproductive Immunology · 2025
DOI: 10.1111/aji.70080 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Reproductive Immunology, 2025. Verfasst von Brandie DePaoli Taylor und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of Basic Science and Translational Research, University of Texas Medical Branch, Galveston, Texas, …. Hauptthemen laut MEDLINE: Pre-Eclampsia, Chlamydia trachomatis, Chlamydia Infections, Pregnancy Complications, Infectious. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 149 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Chlamydia trachomatis is the most common bacterial sexually transmitted infection (STI) in the United States. Ascending C. trachomatis can cause pelvic inflammatory disease (PID), potentially leading to subsequent infertility, ectopic pregnancy, and adverse pregnancy outcomes. There is growing evidence implicating infections (e.g., COVID‐19, cytomegalovirus) in preeclampsia etiology, a maternal hypertensive disorder and leading cause of maternal morbidity and mortality. However, few studies have investigated the impact of STIs on preeclampsia risk. In this review, we provide an overview of the potential association between C. trachomatis and preeclampsia and identify future research needs through a critical evaluation of epidemiologic, in vitro, and in vivo studies. Unfortunately, current methodological limitations such as lower‐quality study designs, selection bias, confounding bias, and variations in chlamydia diagnostic methods inhibit our understanding of the impact of C. trachomatis on preeclampsia. In addition, bench‐side approaches such as animal models and in vitro studies have not elucidated the mechanisms linking C. trachomatis to preeclampsia. Understanding the biological pathways that could be disrupted by chlamydia is important as it may ultimately guide the development and use of novel therapeutics to augment standard antibiotic therapy to reduce pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Division of Basic Science and Translational Research, University of Texas Medical Branch, Galveston, Texas, USA.
- Academic Research, Advocate Aurora Research Institute, Milwaukee, Wisconsin, USA.
- Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Brandie DePaoli Taylor, Emmanuel Amabebe, Lauren S Richardson
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Taylor, B. D., Haggerty, C. L., Amabebe, E., & Richardson, L. S. (2025). Current Evidence of Maternal Infection With Chlamydia trachomatis and Preeclampsia Risk. American Journal of Reproductive Immunology. https://doi.org/10.1111/aji.70080
Vancouver
Taylor BD, Haggerty CL, Amabebe E, Richardson LS. Current Evidence of Maternal Infection With Chlamydia trachomatis and Preeclampsia Risk. American Journal of Reproductive Immunology. 2025. doi:10.1111/aji.70080
BibTeX
@article{Taylor2025,
author = {Taylor, Brandie DePaoli and Haggerty, Catherine L and Amabebe, Emmanuel and Richardson, Lauren S},
title = {Current Evidence of Maternal Infection With Chlamydia trachomatis and Preeclampsia Risk},
journal = {American Journal of Reproductive Immunology},
year = {2025},
doi = {10.1111/aji.70080}
}
EUVIMED